TMCnet News
NOMADX Holdings LLC Launches to Commercialize its Rapid and Highly Sensitive Biological and Chemical Detection Platform and Portfolio of Automated Testing ApplicationsNOMADX Holdings LLC ("NOMADX Holdings"), a private company pioneering new technologies for biological and chemical detection, announced today that it has commenced operations to commercialize a portfolio of innovative products that will enable faster, more accurate portable testing in food, water, and air safety, as well as human healthcare, applications. NOMADX Holdings, which is an acronym for Nano-Molecular Automated Diagnostics, was founded by Wilson Chatterji Ventures ("WCV") and catalyzed through the asset purchase agreement of RamanID, Inc., founded by Ms. Reem Mahrat, earlier this year. The transaction was facilitated by law firm Foley & Lardner. WCV co-founder and life sciences and med-tech investor and expert, Anjan Chatterji, JD, MBA, LLM, will serve as Chief Executive Officer and Board Member of NOMADX. Chris Wilson, WCV partner and a 30-year senior partner of a multi-billion-dollar hedge fund, has been appointed Chairman of the NOMADX Board. Rounding out the NOMADX senior leadership team are a group of experienced industry executives who will operate from the company's offices in New York City, New Delhi, India, and Boise, Idaho. They include:
"We are pleased to announce the launch of NOMADX Holdings, the natural selection in the evolution of food safety and human healthcare. The COVID pandemic saw a dramatic rise in the use of testing and created a positive perception of its value in the public. Despite the rapid introduction of tests during this time, it was also clear that very little innovation has taken place in portable, rapid testing over the last 20 years. We also saw the potential for contamination and the testing industry pushed past its limits. This led us to look at ways to disrupt this market and to the founding of NOMADX Holdings," said Chatterji. "NOMADX aims to commercialize a new generation of powerful detection systems that will enable anyone to perform accurate, rapid, and cost-effective environmental and biological testing. This is not just a step forward, it's the true allowance of natural selection to advance the evolution of much needed preemptive and offensive technologies and applied applications that enable a safer, healthier future for us all." The first commercial application of the NOMADX platform will enable on-site testing for the food safety and public water utilities industries. Foodborne illness, alone, is a preventable public health challenge and multi-billion-dollar burden. The World Health Organization ("WHO") estimated in 2022 that 600 million - almost 1 in 10 people in the world - fall ill after eating contaminated food and 420,000 die every year, resulting in the loss of 33 million healthy life years. The WHO also estimates 1.7 billion people use a drinking water source contaminated with feces. Further, peer-reviewed studies have shown that approximately 80% of diseases and 50% of child deaths worldwide are related to poor water quality. The NOMADX platform utilizes label- and label-free testing, on a portable proprietary device, and can detect trace amounts of contaminants, including, but not limited to Salmonella, Listeria monocytogenes, Escherichia coli, PFAS, as well as clinical biomarkers, viruses, and other clinical applications using multi-plex technology on a single chip. With a minute or less of sample prep, rapid testing can be done at a very low cost on food, its packaging, and preparation surfaces, and can also be used for the automated detection of contaminants in water, air, and in vitro. The cartridge and sample, after testing, can be retained for confirmatory testing, as the NOMADX protocol is non-destructive to the sample. Further, spectral data are analyzed with the NOMADX data library and AI-based algorithm to produce results instantly for defined pathogen signatures, as well as those that have corollary signatures that have not yet been defined. The NOMADX platform pipeline will expand to include early detection in the field of oncology and rare diseases, as well as potential therapeutics for companion diagnostics. For more information about NOMADX platform and the company's early access program, please visit: www.nomadxholdings.com. About NOMADX Holdings NOMADX Holdings LLC, is pioneering new technologies for biological and chemical detection that include innovative products that will enable faster, more accurate testing in food, water, and air safety as well as human healthcare, applications. For more information about NOMADX and its mission to become the natural selection in the evolution of diagnostics, please visit www.nomadxholdings.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240501125379/en/ |
